ClinicalTrials.gg
RecruitingNCT07453147MCATTsUpdated Mar 5, 2026

Selective Versus Contiguous Connective Tissue Grafts in the Modified Tunnel Technique

An interventional study of Selective/Segmented graft and Continuous graft in Gum Recession, sponsored by Centre Hospitalier Universitaire de Liege. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by Centre Hospitalier Universitaire de Liege · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Sep 2025, registered Dec 2025).
  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this study is to evaluate how effective a gum grafting procedure is in treating gum recession that affects several teeth. Gum recession happens when the gum tissue pulls away from the tooth, exposing the roots. The study will look at how the treatment improves gum health, appearance, and function.

A total of 32 patients will take part in the study. All patients will be treated with a modified coronally advanced tunnel. For half of them of contiguous graft will be used, for the other half a segmented graft.

Data collected will include medical history, dental and aesthetic information, clinical measurements, and a digital scan of the mouth.

The study will include the following steps:

Before the procedure: You will have a clinical and X-ray examination to determine how much your gums have receded. A digital impression of your teeth will also be taken.

Surgical procedure: You will receive a gum graft to cover the exposed roots. This involves moving gum tissue, often taken from the roof of your mouth, to the affected areas.

After the procedure: You will have several follow-up visits over a few months to check your healing and the results of the treatment.

Study timeline:

The surgery will be done once. Follow-up visits will take place 1, 3, 6, and 12 months after the surgery. The total duration of the study is about 12 months.

02

Conditions studied

  • Gum Recession

Browse trials for

Keywords

  • Gum recession
  • Recession treatment
  • Tunnel technique
  • Connective tissue graft
  • Gingival recession
03

In context

Gingival Recession

430 studies on the registry are indexed under Gingival Recession; 105 are open to participants now.

This study's planned enrollment of 32 is close to the median of 30 across 394 interventional studies indexed under Gingival Recession.

Browse Gingival Recession studies →

Lead sponsor

Centre Hospitalier Universitaire de Liege is the lead sponsor of 40 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or ASA II
  • Good periodontal health
  • Able to undergo oral surgery
  • Must be 18 years old and older
  • No smoking
  • At least two teeth in the same sector in the maxilla and the right and left mandible (except in the mandibular incisive sector), of which at least 2 are contiguous, with vestibular gingival recessions of type RT 1 of 1-5mm (Cairo et al. 2011)
  • An identifiable or restorable cemento-enamel junction (CEJ), with or without the presence of a non-carious cervical lesion (Pini-Prato et al. 2010)
  • Plaque index (O'Leary 1972) and bleeding index (Ainamo et al. 1975) scores of less than 20%
  • Able to give and have signed the consent forms

Exclusion criteria

Exclusion Criteria:

  • Teeth showing recession associated with a carious lesion, restoration or cervical prosthesis involving CEJ
  • Teeth with recession depth >5mm
  • Molars with recessions will be treated but will not be taken into account for the measurements
  • Teeth with recession that have already undergone periodontal surgery
  • Presence of severe tooth malposition, rotation or significant version of the tooth
  • Smoker and ex-smoker
  • Patient suffering from a disease affecting the periodontium
  • Patient with clinical signs of active periodontitis
  • Known pregnancy in progress or breastfeeding
  • to surgery
  • Conditions or circumstances which would prevent completion of study participation or interfere with analysis of study results, such as history of no-compliance or unreliability
  • Patients deprived of their liberty or under legal protection
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Selective/Segmented graft

    In this group a segmented CTG will be used

    Procedure: Selective/Segmented graft

  • Active comparator
    Continuous graft

    In this group a continuous CTG will be used

    Procedure: Continuous graft

Interventions

  • ProcedureSelective/Segmented graft

    In this group a segmented CTG will be used

  • ProcedureContinuous graft

    In this group a continuous CTG will be used

06

What researchers measure

Primary outcomes

  1. Digital complete root coverage

    defined as the presence/absence of complete coverage of the recession at the mid-buccal aspect. It will be evaluated by taking the CEJ as a reference line, at the different timepoints, analysed digitally using the digital impression

    Time frame: 3, 6 and 12 months

Secondary outcomes

  1. Complete Root Coverage

    defined as the presence/absence of complete coverage of the recession at the mid-buccal aspect. It will be evaluated by taking the CEJ as a reference line, at the different timepoints.

    Time frame: 3, 6 and 12 months

  2. Mean Root Coverage

    defined as the percentage of root coverage in the mid-buccal aspect, taking baseline as a refer-ence. It equals to difference of the linear distance (in mm, using probe) between the mid-buccal point of the CEJ and the mid-buccal margin at baseline and different timepoints, divided by the distance between the mid buccal point of the CEJ and the mid buccal margin at baseline. The MRC will be measured as percentage (%).

    Time frame: 3, 6 and 12 months

  3. Keratinized Tissue Height

    Defined as the linear height of keratinized tissue, measured between the mid-buccal gingival mar-gin of the treated tooth and the muco-gingival junction (in mm using a probe). It will be measured at baseline and at the different timepoints.

    Time frame: 3, 6 and 12 months

  4. Recession reduction

    defined as the linear reduction in recession (in mm using a probe), at the mid buccal aspect, be-tween baseline and the different timepoints. It will be measured at the different timepoints.

    Time frame: 3, 6 and 12 months

  5. Dental hypersensitivity

    Assessed by 10 s air spray applied to the buccal cervical area (yes/no).

    Time frame: 3, 6 and 12 months

  6. Root-coverage Esthetic Score

    Evaluated at the different timepoints according to Cairo et al. (2009).

    Time frame: 3, 6 and 12 months

  7. Digital mean root coverage

    Defined as the percentage of root coverage in the mid-buccal aspect, taking baseline as a refer-ence. Measured by dividing the mean surface (in mm²) of the root covered by the procedure by the mean surface (in mm²) of root exposed at baseline. Measured digitally at 3-6 months and 1 year after surgery. \[(Initial Exposed Root Surface(mm2) - Post-operative exposed root surface(mm2)) / Initial Exposed Root Surface(mm2)\] x 100%.

    Time frame: 3, 6 and 12 months

  8. Digital recession reduction

    defined as the reduction in recession (in mm², measured digitally), at the mid-buccal aspect, be-tween baseline and the different timepoints. It will be measured at the different timepoints.

    Time frame: 3, 6 and 12 months

  9. Digital Gingival soft tissues profile

    Defined as the change in gingival soft tissue thickness between baseline and the different timepoints, measured at the mid buccal aspect, between baseline and the different timepoints tak-ing CEJ as reference.

    Time frame: 3, 6 and 12 months

  10. Volumetric Changes

    evaluated as 3D changes in the volume of gingival tissue between different timepoints, measured using the digital impression.

    Time frame: 3, 6 and 12 months

  11. Patient Reported Outcome Measures

    Self-perceived pain: Reported on a 100mm VAS scale ranging from 0 (no pain at all) to 100 (worst pain possible). Number, nature and frequency of medication: Patients will be asked to report every take of medica-tion (substance, posology, and time of the day). Swelling: Reported on a 100 mm VAS scale ranging from 0 (no swelling at all) to 100 (worst swelling possible). T Bleeding: Reported on a 100 mm VAS scale ranging from 0 (no bleeding at all) to 100 (worst bleed-ing possible). Discomfort during surgery: Reported on a 100 mm VAS scale ranging from 0 (no discomfort at all) to 100 (a lot of discomfort). Self-perceived hypersensitivity Aesthetic outcome (self-evaluation): Reported on a 100 mm VAS scale ranging from 0 (no not satis-fied at all) to 100 (best outcome they could imagine). Report other adverse effects/ complications

    Time frame: 1, 2, 3, 4, 5, 6, 7, 14 days and 3, 6, 12 months

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2028, 36 months after the start.

Of 237 non-industry interventional studies with no phase under Gingival Recession, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 30. This study's planned 36 months is above that.

Counting every sponsor, half of 239 studies reached it within 19 months; a quarter within 11 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2025
First posted
Mar 5, 2026
StartActual
Sep 1, 2025
Primary completionEst.
Sep 1, 2028
CompletionEst.
Sep 1, 2028
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07453147
Lead sponsor
Centre Hospitalier Universitaire de Liege
Collaborators
26K Center for Clinical Research
Responsible party
Isabelle Laleman (Prof. Dr., Centre Hospitalier Universitaire de Liege) — Principal investigator
First posted
Mar 5, 2026
Start date
Sep 1, 2025
Primary completion
Sep 1, 2028 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Mar 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion